Dengxiong Li , Jie Wang , Xinrui Li , Zhipeng Wang , Qingxin Yu , Siang Boon Koh , Ruicheng Wu , Luxia Ye , Yiqing Guo , Uzoamaka Okoli , Alisha Pati-Alam , Eduardo Mota , Wuran Wei , Koo Han Yoo , William C. Cho , Dechao Feng , Susan Heavey
{"title":"Interactions between radiotherapy resistance mechanisms and the tumor microenvironment","authors":"Dengxiong Li , Jie Wang , Xinrui Li , Zhipeng Wang , Qingxin Yu , Siang Boon Koh , Ruicheng Wu , Luxia Ye , Yiqing Guo , Uzoamaka Okoli , Alisha Pati-Alam , Eduardo Mota , Wuran Wei , Koo Han Yoo , William C. Cho , Dechao Feng , Susan Heavey","doi":"10.1016/j.critrevonc.2025.104705","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Resistance to radiotherapy (RT) presents a significant clinical challenge in management of cancer. Recent evidence points to specific mechanisms of resistance within the tumor microenvironment (TME), which we aim to discuss, with the aim of overcoming the clinical challenge.</div></div><div><h3>Methods</h3><div>We performed the narrative review using PubMed and Web of Science databases to identify studies that reported the regulative network and treatments of RT resistance from TME perspectives.</div></div><div><h3>Results</h3><div>RT significantly changes the immune TME of cancers, which is closely appearing to play a key role in RT resistance (RTR) by modulating immune cell infiltration and function. Various phenotypes are involved in the development of RTR, such as autophagy, senescence, oxidative stress, cell polarization, ceramide metabolism, and angiogenesis in the TME. Key genes and pathways are also implicated in RTR, including immune and inflammatory cytokines, TGF-β, P53, the NF-κB pathway, the cGAS/STING pathway, the ERK and AKT pathway, and the STAT pathway. Based on the mechanism of RTR in the TME, many proposed routes to overcome RTR, several specifically target the TME including targeting fibroblast activation protein, exosomes management, nanomedicine, and immunotherapy. Many challenges in RT resistance still need to be further explored with emerging investigative methods, such as artificial intelligence, genetic technologies, and bioengineering.</div></div><div><h3>Conclusions</h3><div>The complex interactions between RT and TME significantly affect the efficiency of RT. Novel approaches to overcome this clinical difficulty are promising, which needs future work to further explore and identify better treatment strategies.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"210 ","pages":"Article 104705"},"PeriodicalIF":5.6000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1040842825000939","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Resistance to radiotherapy (RT) presents a significant clinical challenge in management of cancer. Recent evidence points to specific mechanisms of resistance within the tumor microenvironment (TME), which we aim to discuss, with the aim of overcoming the clinical challenge.
Methods
We performed the narrative review using PubMed and Web of Science databases to identify studies that reported the regulative network and treatments of RT resistance from TME perspectives.
Results
RT significantly changes the immune TME of cancers, which is closely appearing to play a key role in RT resistance (RTR) by modulating immune cell infiltration and function. Various phenotypes are involved in the development of RTR, such as autophagy, senescence, oxidative stress, cell polarization, ceramide metabolism, and angiogenesis in the TME. Key genes and pathways are also implicated in RTR, including immune and inflammatory cytokines, TGF-β, P53, the NF-κB pathway, the cGAS/STING pathway, the ERK and AKT pathway, and the STAT pathway. Based on the mechanism of RTR in the TME, many proposed routes to overcome RTR, several specifically target the TME including targeting fibroblast activation protein, exosomes management, nanomedicine, and immunotherapy. Many challenges in RT resistance still need to be further explored with emerging investigative methods, such as artificial intelligence, genetic technologies, and bioengineering.
Conclusions
The complex interactions between RT and TME significantly affect the efficiency of RT. Novel approaches to overcome this clinical difficulty are promising, which needs future work to further explore and identify better treatment strategies.
背景:放射治疗耐药(RT)是癌症治疗的一个重要的临床挑战。最近的证据指向肿瘤微环境(TME)内的特定耐药机制,我们旨在讨论这些机制,以克服临床挑战。方法:我们使用PubMed和Web of Science数据库进行叙述性回顾,从TME的角度确定报道RT耐药的调控网络和治疗的研究。结果:RT可显著改变肿瘤的免疫TME,其可能通过调节免疫细胞浸润和功能,在RT耐药(RTR)中发挥关键作用。RTR的发生涉及多种表型,如TME中的自噬、衰老、氧化应激、细胞极化、神经酰胺代谢和血管生成。RTR的关键基因和通路包括免疫和炎症细胞因子、TGF-β、P53、NF-κB通路、cGAS/STING通路、ERK和AKT通路以及STAT通路。基于RTR在TME中的作用机制,人们提出了许多克服RTR的途径,其中一些专门针对TME,包括靶向成纤维细胞激活蛋白、外泌体管理、纳米药物和免疫治疗。RT耐药性方面的许多挑战仍需要通过人工智能、基因技术和生物工程等新兴研究方法进一步探索。结论:RT和TME之间复杂的相互作用显著影响RT的疗效,克服这一临床难题的新方法是有希望的,需要未来的工作进一步探索和确定更好的治疗策略。
期刊介绍:
Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.